H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on Oruka Therapeutics (ORKA) to $40 from $45 and keeps a Buy rating on the shares. The firm cites the company’s recent equity financing for the target drop.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORKA:
- Oruka Therapeutics initiated with an Overweight at Barclays
- Oruka Therapeutics files to sell 39.43M shares of common stock for holders
- Promising Future for Oruka Therapeutics: Buy Rating Backed by ORKA-002’s Market Potential and Strategic Expansion
- Oruka Therapeutics’ ORKA-002: Promising Alternative with Competitive Edge in Hidradenitis Suppurativa and Psoriasis
- Leerink sees greater opportunity for Oruka’s ORKA-002 after MoonLake news